Table 1 Patient demographics and symptoms at initial diagnosis
SACQ (170) | SQCQ (187) | p | |
|---|---|---|---|
Age at diagnosis (years) | 32.09 ± 14.35 | 38.61 ± 15.08 | < 0.001 |
Gender (male: female) | 21:149 | 19:168 | 0.512 |
Time to get SACQ/SQCQ (months) | 22.55 (12.70, 50.36) | 18.07 (10.47, 36.53) | 0.036 |
Follow-up time (months) | 50.43 (32.93, 82.69) | 53.17 (30.40, 80.73) | 0.706 |
The SACQ/SQCQ period (months) | 20.30 (10.64, 33.49) | 24.00 (12.00, 43.30) | 0.028 |
Dose of antimalarials at the start of SACQ/SQCQ (g) | 0.20 (0.20, 0.40) | 0.20 (0.20, 0.40) | 0.058 |
Taking immunosuppressants at the start of SACQ/SQCQ (%) | 96/170 (56.5%) | 99/187 (52.9) | 0.504 |
LN | 62 (36.5%) | 68 (36.4%) | 0.983 |
NPSLE | 8 (4.7%) | 11 (5.9%) | 0.621 |
Thrombocytopenia | 23/170 (13.5%) | 36/187 (19.3%) | 0.146 |
Hemolytic anemia | 14/170 (8.2%) | 14/187 (7.5%) | 0.793 |
Pulmonary hypertension | 4/170 (2.4%) | 5/187 (2.7%) | 1.000 |
Myocardial involvement | 0/170 (0) | 3/187 (1.6%) | 0.281 |
ILD | 3/170 (1.8%) | 6/187 (3.2%) | 0.595 |
Alveolar hemorrhage | 0/170 (0) | 0/187 (0) | NA |
Smooth muscle involvement | 6/170 (3.5%) | 5/187 (2.7%) | 0.640 |
Polyserositis | 8/170 (4.7%) | 8/187 (4.3%) | 0.845 |
APS | 7/170 (4.1%) | 5/187 (2.7%) | 0.450 |
TTP or TMA | 0/170 (0) | 0/187 (0) | NA |
Secondary SS | 19/170 (11.2%) | 25/187 (13.4%) | 0.529 |